Glioblastoma is an aggressive form of brain cancer. Less than 5 percent of patients diagnosed with this cancer type will survive for five years or more. Glioblastoma is notoriously difficult to treat, and new avenues...
People who have inherited BRCA mutations and are at high risk for cancer recurrence may benefit from a PARP inhibitor.
Patient volume at radiation therapy clinics can affect outcomes, and more news of the week from Cancer Today.
The use of lymphocytes to attack tumors may be less effective if given after other treatments, study published in an AACR journal indicates. Sooner rather than later may be the best strategy for using...
The U.S. FDA granted accelerated approval to an immunotherapeutic and a companion diagnostic test to treat certain cancer patients whose tumors have a specific biomarker. The U.S. Food and Drug Administration (FDA) granted accelerated approval to...
Survival is not affected by delaying breast cancer treatment for fertility preservation, and more news of the week from Cancer Today.
The U.S. FDA approved a molecularly targeted therapeutic for certain patients with tumors associated with a raRe genetic disorder—von Hippel-Lindau disease. The U.S. Food and Drug Administration (FDA) approved belzutifan (Welireg), a targeted therapy for...
The U.S. FDA approved the combination of lenvatinib and pembrolizumab to treat adult patients with renal cell carcinoma, the most common form of kidney cancer. The U.S. Food and Drug Administration (FDA) approved the...
The father of a child diagnosed with brain cancer calls for better financial support for families, and more news of the week from Cancer Today.
Remetinostat, a topical therapy that works by inhibiting the expression of cancer-promoting genes, could reduce the need for surgical removal of many subtypes of basal cell carcinoma lesions.
AACR Fellow Lewis C. Cantley, PhD, leads a national effort targeting triple-negative breast cancer and ovarian cancer with a novel drug combination.
Learn MoreYour donation to the American Association for Cancer Research helps our more than 58,000 members worldwide drive progress against cancer.
Donate Now